776 related articles for article (PubMed ID: 29929548)
1. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
2. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
6. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
7. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
8. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
10. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
12. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
13. Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis.
He L; Wang Y; Wu Q; Song Y; Ma X; Zhang B; Wang H; Huang Y
BMC Womens Health; 2020 Sep; 20(1):194. PubMed ID: 32891135
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
[TBL] [Abstract][Full Text] [Related]
16. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
Ogiya R; Niikura N; Kumaki N; Bianchini G; Kitano S; Iwamoto T; Hayashi N; Yokoyama K; Oshitanai R; Terao M; Morioka T; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Cancer Sci; 2016 Dec; 107(12):1730-1735. PubMed ID: 27727484
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]